LeaderPortfolio
Mazumdar-Shaw
Kiran Mazumdar-Shaw
Rank #1168
INDIAHealthcareBiopharmaceuticals

Kiran Mazumdar-Shaw

Net Worth
$3.63B
-0.06% (24h)
Kiran Mazumdar-Shaw, born in 1953, is an Indian billionaire entrepreneur and the Executive Chairperson of Biocon Limited and Biocon Biologics Limited. Her source of wealth stems from her pioneering work in biopharmaceuticals. With a career spanning over four decades, she transformed Biocon from an industrial enzymes manufacturer into a leading biopharmaceutical company focused on accessible and affordable medicines. Her achievements have earned her recognition as a global business leader and a champion of healthcare innovation. With a net worth of $3.5 billion in 2024, she continues to drive advancements in the healthcare industry and contribute significantly to philanthropic causes.

How to read Kiran Mazumdar-Shaw's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Kiran Mazumdar-Shaw, we anchor the narrative to Biopharmaceuticals and Biopharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $3.63B alongside global rank #1168, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (INDIA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Kiran Mazumdar-Shaw was born on March 23, 1953, in Bangalore, India. She completed her schooling at Bishop Cotton Girl's High School and earned a bachelor's degree in Zoology from Bangalore University in 1973. She furthered her education by obtaining a master's degree in brewing from Ballarat University in Australia in 1975. Despite initially planning a career in medicine, she was unable to secure a scholarship and instead pursued her interest in brewing science.

Rise to Success

Kiran Mazumdar-Shaw founded Biocon India in 1978 with a modest capital of ₹10,000. Initially focusing on industrial enzymes, she steered the company into the biopharmaceuticals sector. She spearheaded the company's growth, making Biocon the first biotechnology company in India to launch an IPO. Her strategic vision and innovative approach led to the development of affordable medicines, establishing her as a prominent figure in the biotech industry.

Key Business Strategies

Kiran Mazumdar-Shaw's business strategies centered on innovation, research, and strategic partnerships. She transformed Biocon into a fully integrated biopharmaceutical company with a diversified portfolio of products. She established subsidiaries like Syngene and Clinigene (later merged) to support research and clinical trials. Her focus on biosimilars and affordable innovation has been key to Biocon's success, allowing it to reach over 21 million patients across 120 countries as of FY25.

Philanthropy

Kiran Mazumdar-Shaw is committed to philanthropic endeavors, particularly in healthcare. She established the Biocon Foundation, which focuses on health, education, and infrastructure in rural areas. She has also founded the Mazumdar-Shaw Medical Foundation, which supports cancer research and treatment. In 2015, she signed the Giving Pledge, committing to donate a significant portion of her wealth to philanthropic causes. She believes in affordable healthcare and is working to improve the lives of people through affordable innovation.

Career Timeline

2020

EY World Entrepreneur Of The Year

Recognized as EY World Entrepreneur Of The Year.

2005

Padma Bhushan Award

Awarded Padma Bhushan for her pioneering work in industrial biotechnology.

2004

Biocon IPO

Successfully listed Biocon on the stock market.

1989

Padma Shri Award

Awarded Padma Shri by the Indian government for her contributions to industrial biotechnology.

1978

Founded Biocon India

Established Biocon, focusing on industrial enzymes and later biopharmaceuticals.

Philanthropic Impact

Health, Education, Infrastructure$33M (cumulative)

Biocon Foundation

Focuses on health, education, and infrastructure, especially in rural areas.

HealthcareUndisclosed

Mazumdar-Shaw Medical Foundation

Supports cancer research and treatment.

Education1M

Mazumdar-Shaw Scholarship Fund

Provide scholarships to students pursuing careers in community medicine.

Key Business Ventures & Holdings

CompanyStakeValue
Biocon

Net Worth History

In-Depth Analysis

Early Life and Education

Kiran Mazumdar-Shaw was born on March 23, 1953, in Bangalore, India. She completed her schooling at Bishop Cotton Girl's High School and earned a bachelor's degree in Zoology from Bangalore University in 1973. She furthered her education by obtaining a master's degree in brewing from Ballarat University in Australia in 1975. Despite initially planning a career in medicine, she was unable to secure a scholarship and instead pursued her interest in brewing science.

Rise to Success

Kiran Mazumdar-Shaw founded Biocon India in 1978 with a modest capital of ₹10,000. Initially focusing on industrial enzymes, she steered the company into the biopharmaceuticals sector. She spearheaded the company's growth, making Biocon the first biotechnology company in India to launch an IPO. Her strategic vision and innovative approach led to the development of affordable medicines, establishing her as a prominent figure in the biotech industry.

Key Business Strategies

Kiran Mazumdar-Shaw's business strategies centered on innovation, research, and strategic partnerships. She transformed Biocon into a fully integrated biopharmaceutical company with a diversified portfolio of products. She established subsidiaries like Syngene and Clinigene (later merged) to support research and clinical trials. Her focus on biosimilars and affordable innovation has been key to Biocon's success, allowing it to reach over 21 million patients across 120 countries as of FY25.

Philanthropy

Kiran Mazumdar-Shaw is committed to philanthropic endeavors, particularly in healthcare. She established the Biocon Foundation, which focuses on health, education, and infrastructure in rural areas. She has also founded the Mazumdar-Shaw Medical Foundation, which supports cancer research and treatment. In 2015, she signed the Giving Pledge, committing to donate a significant portion of her wealth to philanthropic causes. She believes in affordable healthcare and is working to improve the lives of people through affordable innovation.

Data Sources & Methodology

Figures for Kiran Mazumdar-Shaw are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.